Clinica Chimica Acta:循环生长分化因子-15、kruppel样因子4和生长阻滞剂特异性6与冠心病的关系

2019-10-17 gladiator MedSci原创

目前用于急性胸痛患者的评估工具要么是创伤性的(冠状动脉造影),要么可靠性较差(心肌肌钙蛋白浓度的测量)。

目前用于急性胸痛患者的评估工具要么是创伤性的(冠状动脉造影),要么可靠性较差(心肌肌钙蛋白浓度的测量)。我们研究了新的心血管应激标志物、血清生长分化因子-15 (GDF-15)kruppel样因子4 (KLF4)和生长抑制因子特异性6 (gas6)是否可能成为冠心病(CAD)的有用生物标志物。

根据冠状动脉造影,本研究共纳入350名男性患者,包括198名冠心病患者和152名对照组。采用酶联免疫吸附试剂盒检测GDF-15KLF4gas6浓度。采用多因素logistic回归和多因素线性回归分析GDF-15KLF4gas6与冠心病风险或冠心病严重程度之间的关系。

血清GDF-15KLF4GAS6浓度男性患者显著高于CAD比对照组(P <0.05),且它们与冠状血管介入(P <0.05)显著相关。调整混杂因素后,我们发现,循环GDF-15浓度保持正与CAD的存在(比值比[OR]1标准差[SD]增加,3.182; 95%置信区间[CI] 1.5866.382 ; P = 0.001),象KLF4浓度(OR1-SD增加,13.05; 95CI 2.94057.921P = 0.001)。此外,循环GDF-15浓度呈正Gensini评分(每1-SD增加估计SD改变,22.091; 95CI 9.14735.035P = 0.001)相关联,因为是KLF4浓度(每1-估计SD变化SD增加,27.996; 95CI 10.082 45.910到,P = 0.002)。 相比之下,Gas6CADGensini评分无关。

在本病例对照研究中,循环GDF-15KLF4浓度升高与冠心病的存在和严重程度显著相关。

原始出处:

Huan LiuYong-nan LyuAssociation of circulating growth differentiation factor-15, Krüppel-like factor 4 and growth arrest-specific 6 with coronary artery disease

本文系梅斯医学(MedSci)原创编译整理,转载需授权!


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2040049, encodeId=05ca2040049de, content=<a href='/topic/show?id=b4a96960808' target=_blank style='color:#2F92EE;'>#生长分化因子-15#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69608, encryptionId=b4a96960808, topicName=生长分化因子-15)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Tue Jun 09 09:19:00 CST 2020, time=2020-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1849767, encodeId=6bd81849e67ba, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Fri Jul 17 09:19:00 CST 2020, time=2020-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2085829, encodeId=3cbf2085829f5, content=<a href='/topic/show?id=723a9e69383' target=_blank style='color:#2F92EE;'>#阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97693, encryptionId=723a9e69383, topicName=阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40be178, createdName=zhyy88, createdTime=Thu Jul 30 09:19:00 CST 2020, time=2020-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899333, encodeId=10f11899333f7, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Thu Jan 09 14:19:00 CST 2020, time=2020-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728170, encodeId=edbc1e28170a9, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Fri Jan 31 05:19:00 CST 2020, time=2020-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1625839, encodeId=e98f162583966, content=<a href='/topic/show?id=bc29140196e' target=_blank style='color:#2F92EE;'>#PEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14019, encryptionId=bc29140196e, topicName=PEL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=399320916411, createdName=tidiq, createdTime=Sat Oct 19 13:19:00 CST 2019, time=2019-10-19, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2040049, encodeId=05ca2040049de, content=<a href='/topic/show?id=b4a96960808' target=_blank style='color:#2F92EE;'>#生长分化因子-15#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69608, encryptionId=b4a96960808, topicName=生长分化因子-15)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Tue Jun 09 09:19:00 CST 2020, time=2020-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1849767, encodeId=6bd81849e67ba, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Fri Jul 17 09:19:00 CST 2020, time=2020-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2085829, encodeId=3cbf2085829f5, content=<a href='/topic/show?id=723a9e69383' target=_blank style='color:#2F92EE;'>#阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97693, encryptionId=723a9e69383, topicName=阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40be178, createdName=zhyy88, createdTime=Thu Jul 30 09:19:00 CST 2020, time=2020-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899333, encodeId=10f11899333f7, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Thu Jan 09 14:19:00 CST 2020, time=2020-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728170, encodeId=edbc1e28170a9, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Fri Jan 31 05:19:00 CST 2020, time=2020-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1625839, encodeId=e98f162583966, content=<a href='/topic/show?id=bc29140196e' target=_blank style='color:#2F92EE;'>#PEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14019, encryptionId=bc29140196e, topicName=PEL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=399320916411, createdName=tidiq, createdTime=Sat Oct 19 13:19:00 CST 2019, time=2019-10-19, status=1, ipAttribution=)]
    2020-07-17 windight
  3. [GetPortalCommentsPageByObjectIdResponse(id=2040049, encodeId=05ca2040049de, content=<a href='/topic/show?id=b4a96960808' target=_blank style='color:#2F92EE;'>#生长分化因子-15#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69608, encryptionId=b4a96960808, topicName=生长分化因子-15)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Tue Jun 09 09:19:00 CST 2020, time=2020-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1849767, encodeId=6bd81849e67ba, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Fri Jul 17 09:19:00 CST 2020, time=2020-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2085829, encodeId=3cbf2085829f5, content=<a href='/topic/show?id=723a9e69383' target=_blank style='color:#2F92EE;'>#阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97693, encryptionId=723a9e69383, topicName=阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40be178, createdName=zhyy88, createdTime=Thu Jul 30 09:19:00 CST 2020, time=2020-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899333, encodeId=10f11899333f7, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Thu Jan 09 14:19:00 CST 2020, time=2020-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728170, encodeId=edbc1e28170a9, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Fri Jan 31 05:19:00 CST 2020, time=2020-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1625839, encodeId=e98f162583966, content=<a href='/topic/show?id=bc29140196e' target=_blank style='color:#2F92EE;'>#PEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14019, encryptionId=bc29140196e, topicName=PEL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=399320916411, createdName=tidiq, createdTime=Sat Oct 19 13:19:00 CST 2019, time=2019-10-19, status=1, ipAttribution=)]
    2020-07-30 zhyy88
  4. [GetPortalCommentsPageByObjectIdResponse(id=2040049, encodeId=05ca2040049de, content=<a href='/topic/show?id=b4a96960808' target=_blank style='color:#2F92EE;'>#生长分化因子-15#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69608, encryptionId=b4a96960808, topicName=生长分化因子-15)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Tue Jun 09 09:19:00 CST 2020, time=2020-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1849767, encodeId=6bd81849e67ba, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Fri Jul 17 09:19:00 CST 2020, time=2020-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2085829, encodeId=3cbf2085829f5, content=<a href='/topic/show?id=723a9e69383' target=_blank style='color:#2F92EE;'>#阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97693, encryptionId=723a9e69383, topicName=阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40be178, createdName=zhyy88, createdTime=Thu Jul 30 09:19:00 CST 2020, time=2020-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899333, encodeId=10f11899333f7, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Thu Jan 09 14:19:00 CST 2020, time=2020-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728170, encodeId=edbc1e28170a9, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Fri Jan 31 05:19:00 CST 2020, time=2020-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1625839, encodeId=e98f162583966, content=<a href='/topic/show?id=bc29140196e' target=_blank style='color:#2F92EE;'>#PEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14019, encryptionId=bc29140196e, topicName=PEL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=399320916411, createdName=tidiq, createdTime=Sat Oct 19 13:19:00 CST 2019, time=2019-10-19, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2040049, encodeId=05ca2040049de, content=<a href='/topic/show?id=b4a96960808' target=_blank style='color:#2F92EE;'>#生长分化因子-15#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69608, encryptionId=b4a96960808, topicName=生长分化因子-15)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Tue Jun 09 09:19:00 CST 2020, time=2020-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1849767, encodeId=6bd81849e67ba, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Fri Jul 17 09:19:00 CST 2020, time=2020-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2085829, encodeId=3cbf2085829f5, content=<a href='/topic/show?id=723a9e69383' target=_blank style='color:#2F92EE;'>#阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97693, encryptionId=723a9e69383, topicName=阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40be178, createdName=zhyy88, createdTime=Thu Jul 30 09:19:00 CST 2020, time=2020-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899333, encodeId=10f11899333f7, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Thu Jan 09 14:19:00 CST 2020, time=2020-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728170, encodeId=edbc1e28170a9, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Fri Jan 31 05:19:00 CST 2020, time=2020-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1625839, encodeId=e98f162583966, content=<a href='/topic/show?id=bc29140196e' target=_blank style='color:#2F92EE;'>#PEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14019, encryptionId=bc29140196e, topicName=PEL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=399320916411, createdName=tidiq, createdTime=Sat Oct 19 13:19:00 CST 2019, time=2019-10-19, status=1, ipAttribution=)]
    2020-01-31 feather89
  6. [GetPortalCommentsPageByObjectIdResponse(id=2040049, encodeId=05ca2040049de, content=<a href='/topic/show?id=b4a96960808' target=_blank style='color:#2F92EE;'>#生长分化因子-15#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69608, encryptionId=b4a96960808, topicName=生长分化因子-15)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Tue Jun 09 09:19:00 CST 2020, time=2020-06-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1849767, encodeId=6bd81849e67ba, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Fri Jul 17 09:19:00 CST 2020, time=2020-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2085829, encodeId=3cbf2085829f5, content=<a href='/topic/show?id=723a9e69383' target=_blank style='color:#2F92EE;'>#阻滞剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97693, encryptionId=723a9e69383, topicName=阻滞剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=40be178, createdName=zhyy88, createdTime=Thu Jul 30 09:19:00 CST 2020, time=2020-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899333, encodeId=10f11899333f7, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dc7a157, createdName=jinweidong, createdTime=Thu Jan 09 14:19:00 CST 2020, time=2020-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1728170, encodeId=edbc1e28170a9, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Fri Jan 31 05:19:00 CST 2020, time=2020-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1625839, encodeId=e98f162583966, content=<a href='/topic/show?id=bc29140196e' target=_blank style='color:#2F92EE;'>#PEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14019, encryptionId=bc29140196e, topicName=PEL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=399320916411, createdName=tidiq, createdTime=Sat Oct 19 13:19:00 CST 2019, time=2019-10-19, status=1, ipAttribution=)]
    2019-10-19 tidiq

相关资讯

Clinica Chimica Acta:代谢综合征患者IL-10与冠心病严重程度的关系

代谢综合征是增加心脏病风险的危险因素。IL-10在MetS患者冠状动脉疾病(CAD)严重程度中的作用尚不清楚。我们研究了伴有或不伴有严重冠心病的MetS患者血浆中IL-10和其他促炎细胞因子的水平。 · 2019-09-22

-->

任何喝酒都可诱发房颤,没有安全饮酒量

假日心脏综合征,英文名叫Holiday Heart Syndrome,也称为酒精引起的房性心律失常。其特征是没有心脏病的人在大量喝酒后,引起急性心律失常和/或传导障碍。其中,心房颤动最常见。一项研究表明,所有新的房颤发作中有5%~10%归因于饮酒。另一项研究发现,35%的新发房颤和<65岁者63%的房颤与酒精有关。

冠心病应用β阻滞剂严重不规范!报告67家医院1.3万例冠心病患者数据

ESC官网近日报告,在正在举行的第30届长城国际心脏病学会议(GW-ICC)上,阜外医院唐熠达和汪京嘉报告了一项入选我国24城市67家医院1.3万例患者的研究。

Eur J Preven Cardio:3.2万名稳定型冠心病患者研究称,每周一两次高强度运动可降低死亡率

心血管病患者应该适当的运动,那么到底应该怎么制定运动方案?运动的的频率和强度尚有争议。近日,《欧洲预防心脏病杂志》发表的一项研究报告称,每周进行一到两次剧烈的体力活动或能降低稳定型冠心病患者的死亡率。这项称为CLARIFY注册登记研究从非洲、亚洲、澳大利亚、欧洲、中东、北美、中美洲和南美洲的45个国家登记了3.2万例稳定型冠状动脉疾病的门诊患者,随访5年。根据纳入治疗时自我报告的体力活动,患者分为

隐匿性冠心病术中突发室颤并急性心肌梗死抢救成功一例

患者,男,58岁,53kg,诊断为“胆总管结石”,拟在全麻下行腹腔镜胆总管切开取石术。吸烟20余年,每天20支,已戒烟。既往糖尿病史10余年,血糖浓度控制在8~9mmol/L。否认高血压、冠心病等心血管疾病史。血常规提示轻度贫血,胸片、肝功能、凝血四项正常,ASA Ⅱ级,心肺听诊未闻及异常。

物理技术治疗冠心病的实践指南

2002年以来,我国冠心病死亡率总体呈逐年增长趋势,其中农村地区冠心病死亡率上升速度较快。传统的治疗方法,如药物治疗、经皮冠状动脉介入治疗、冠状动脉旁路移植术等治疗方法,虽为冠心病治疗带来较显著的疗效,但是使用传统方法治疗后,仍有多达14%的患者出现持续性心绞痛等症状。针对这些难治性心绞痛的患者还可使用准分子激光冠状动脉斑块消融术(Excimer Laser Coronary Atherectom